Shifts in industry, rather than public, investments are driving changes in the regional biomedical R&D landscape.
The lowdown: Justin Chakma, a venture capital investor at Thomas, McNerney & Partners in La Jolla, California, and his colleagues obtained data on biomedical research and development (R&D) expenditure in the United States, Europe and Asia-Oceania to look at spending trends between 2007 and 2012 (N. Engl. J. Med. 370, 3–6; 2014). While inflation-adjusted expenditure was stable over 5 years, increasing by only US$6.3 billion (2.4%) to $268 billion in 2012, the regional balance of biomedical research funding is changing (see figure).
Biomedical spending in the United States accounted for only 45.4% of the global R&D spend in 2012, when adjusted for purchasing-power parity, down from 51.2% 5 years prior, they report. “The decline is remarkable because the United States has provided a majority of the funding for biomedical R&D globally for the past two decades — a share that some previous analyses suggested was as high as 70 to 80%,” the authors write. Overall, the compound annual growth rate of biomedical spending from 2007 to 2012 in the United States was −1.9%. Other regions that experienced a fall in compound annual growth rates were Europe, of −0.4%, and Canada, of −2.6%.
These losses were mirrored by gains in Asia–Oceania, especially in China and South Korea. The compound annual growth rate from 2007 to 2012 was 32.8% in China, and was 11.4% in South Korea.
The authors also broke funding down by source, comparing levels of public and private funding. The decline of funding in the United States was driven primarily by a $13 billion inflation-adjusted reduction in industry's investment there, they report, to $70 billion in 2012. Public funding in the United States during this time was stable, at $48–49 billion. Industry investment in China, by contrast, grew by $4.8 billion, reaching $6.3 billion in 2012. Public spending in China also grew, by $1.4 billion, to $2 billion.
“One explanation for the shift in global R&D expenditures may be the attractive cost of conducting R&D in Asia–Oceania, where labor is cheaper and greater government subsidies are available,” the authors write. “Accordingly, we found that the US share declined even as global R&D investments by industry remained flat (after adjustment for inflation), which suggests that industry is simply reallocating R&D funding to Asia–Oceania.” National Institutes of Health (NIH) funding alone is unlikely to be a sustainable way of retaining long-term R&D leadership in the United States, they add, and the US government also needs new incentives to induce industry to invest if it wants to stay competitive.
Rights and permissions
About this article
Cite this article
US biomedical R&D spending declines, Asian spending soars. Nat Rev Drug Discov 13, 91 (2014). https://doi.org/10.1038/nrd4244
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4244